AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21999662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day)
Number of subjects: 40
Study 21999662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19218296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 42
Study 19218296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training
Number of subjects: 42
Study 19218296 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 16803911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 1 mug.kg(‐1) iv during induction, continuous infusion at 0.5 mug.kg(‐1).hr(‐1))
Number of subjects: 50
Study 16803911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline, volume-matched bolus and infusion)
Number of subjects: 50
Study 12705367 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal sepsis
Number of subjects: 24
Study 12705367 — intervention group
Group type: COMPARATOR
Intervention: Control (no sepsis)
Number of subjects: 24
Study 11068301 — intervention group
Group type: COMPARATOR
Intervention: Urinary cytology
Number of subjects: 80
Study 11068301 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA image cytometry (conventional analysis of DNA histograms)
Number of subjects: 80
Study 11068301 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA image cytometry (Böcking interpretation)
Number of subjects: 80
Study 11068301 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA image cytometry (grade 1 tumors)
Number of subjects: 80
Study 11068301 — intervention group
Group type: COMPARATOR
Intervention: Both methods (Urinary cytology and DNA image cytometry)
Number of subjects: 80
Study 8807071 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 600 mg/day
Number of subjects: 23
Study 8807071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1361796 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavulanate potentiated ticarcillin (TC)
Number of subjects: 14
Study 6377466 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine daily
Number of subjects: 83
Study 6377466 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg trimipramine daily
Number of subjects: 83
Study 6377466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 29728861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 0
Study 30160183 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened contrast injection (8 seconds) in group A
Number of subjects: 106
Study 30160183 — intervention group
Group type: COMPARATOR
Intervention: Standard contrast injection (10 seconds) in group B
Number of subjects: 106
Study 26656425 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D virtual reality kayak program
Number of subjects: 72
Study 26656425 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise program
Number of subjects: 72
Study 25198417 — intervention group
Group type: EXPERIMENTAL
Intervention: RealConsent
Number of subjects: 743
Study 22541837 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 24
Study 22541837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19394469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice cream (3% butterfat)
Number of subjects: 16
Study 19394469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice cream (9% coconut oil)
Number of subjects: 16
Study 19394469 — intervention group
Group type: COMPARATOR
Intervention: Reduced-fat milk (1.7% milk fat)
Number of subjects: 16
Study 17991635 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.3% trans FA diet
Number of subjects: 30
Study 17991635 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.6% polyunsaturated FA diet
Number of subjects: 30
Study 17991635 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.2% saturated FA diet
Number of subjects: 30
Study 17991635 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL(3)
Number of subjects: 30
Study 17991635 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL(2)
Number of subjects: 30
Study 16884836 — intervention group
Group type: EXPERIMENTAL
Intervention: AgB/RC‐210‐04 (n=136)
Number of subjects: 285
Study 16884836 — intervention group
Group type: COMPARATOR
Intervention: AgB (n=149)
Number of subjects: 285
Study 16884836 — intervention group
Group type: EXPERIMENTAL
Intervention: AgB/RC‐210‐04
Number of subjects: 285
Study 12926838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 million international units (MIU) of oral interferon beta-1a
Number of subjects: 173
Study 12926838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 million international units (MIU) of oral interferon beta-1a
Number of subjects: 173
Study 12926838 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million international units (MIU) of oral interferon beta-1a
Number of subjects: 173
Study 12926838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 12926838 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 173
Study 11005498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal mobilization
Number of subjects: 18
Study 11005498 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of lateral ligaments
Number of subjects: 18
Study 11005498 — intervention group
Group type: COMPARATOR
Intervention: Preservation of lateral ligaments
Number of subjects: 18
Study 8851739 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation of the frame
Number of subjects: 0
Study 8851739 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference task
Number of subjects: 0
Study 1457264 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (4 x 100 micrograms)
Number of subjects: 0
Study 1457264 — intervention group
Group type: COMPARATOR
Intervention: Oral salbutamol (4 mg)
Number of subjects: 0
Study 6363157 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidrine (2 tablets t.i.d. for 8 weeks)
Number of subjects: 39
Study 6363157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets t.i.d. for 8 weeks)
Number of subjects: 39
Study 29313802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training combined with tDCS
Number of subjects: 360
Study 29313802 — intervention group
Group type: COMPARATOR
Intervention: Education training-control combined with sham tDCS
Number of subjects: 360
Study 26324322 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization treatment
Number of subjects: 68
Study 26324322 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement System Impairment (MSI) treatment
Number of subjects: 68
Study 25148644 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone graft (Bio‐Oss) and absorbable collagen membrane (Bio‐Gide)
Number of subjects: 30
Study 25148644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 25148644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 22367794 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (1000 ml/day for 5 days before surgery)
Number of subjects: 244
Study 22367794 — intervention group
Group type: COMPARATOR
Intervention: Control (regular diet)
Number of subjects: 244
Study 22367794 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 244
Study 22367794 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 244
Study 20636739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint
Number of subjects: 52
Study 20636739 — intervention group
Group type: COMPARATOR
Intervention: Bite raising appliance
Number of subjects: 52
Study 18558642 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus day hospital treatment
Number of subjects: 34
Study 18558642 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus day hospital treatment
Number of subjects: 34
Study 16051573 — intervention group
Group type: EXPERIMENTAL
Intervention: Light clothing
Number of subjects: 10
Study 16051573 — intervention group
Group type: COMPARATOR
Intervention: Dark clothing
Number of subjects: 10
Study 12480497 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-2 at doses of 10,000 IU/kg bw
Number of subjects: 18
Study 12480497 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-2 at doses of 1000 IU/kg bw
Number of subjects: 18
Study 12480497 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 10361648 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape intervention (two different approaches)
Number of subjects: 216
Study 10361648 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape portraying recovery as ups and downs
Number of subjects: 216
Study 10361648 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge preparation (control)
Number of subjects: 216
Study 8520751 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 40
Study 8520751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1902866 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/kg intravenous immunoglobulin
Number of subjects: 102
Study 1902866 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/kg intravenous immunoglobulin
Number of subjects: 102
Study 1902866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunoglobulin)
Number of subjects: 102
Study 7295451 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anesthesia
Number of subjects: 0
Study 7295451 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 0
Study 31087630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 0
Study 30238636 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder (2g, 11mg allicin)
Number of subjects: 7
Study 30238636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 28283493 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven Quality Improvement in Primary Care (DQIP) intervention
Number of subjects: 10
Study 25440816 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopy (F‐URS)
Number of subjects: 150
Study 25440816 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 150
Study 25440816 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 150
Study 22957483 — intervention group
Group type: EXPERIMENTAL
Intervention: tongue protector and 0.5 ml AV at 70% three times a day
Number of subjects: 75
Study 22957483 — intervention group
Group type: COMPARATOR
Intervention: tongue protector and 0.5 ml placebo three times a day
Number of subjects: 75
Study 22957483 — intervention group
Group type: COMPARATOR
Intervention: tongue protector three times a day
Number of subjects: 75
Study 21226818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (2.5-50 mg in SAD study; 2.5-20 mg QD for 14 days in MAD study)
Number of subjects: 68
Study 21226818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 3-O-glucuronide (inactive metabolite)
Number of subjects: 68
Study 18784840 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ITN (Serena brand) social marketing plus free ITN (Serena brand) distribution to all pregnant women attending governmental antenatal care services (group A)
Number of subjects: 1050
Study 18784840 — intervention group
Group type: COMPARATOR
Intervention: ITN social marketing only (group B)
Number of subjects: 1050
Study 16609353 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest gated 201Tl myocardial perfusion SPECT
Number of subjects: 81
Study 16609353 — intervention group
Group type: COMPARATOR
Intervention: 2-D echocardiography (2-D ECHO)
Number of subjects: 81
Study 12505559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study 12505559 — intervention group
Group type: COMPARATOR
Intervention: Free choice (FC) control condition
Number of subjects: 0
Study 11027924 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 95
Study 11027924 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 95
Study 8647351 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenoceptor antagonist)
Number of subjects: 25
Study 8647351 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (benzodiazepine)
Number of subjects: 25
Study 8647351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1417632 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 48
Study 1417632 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 48
Study 3883741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil plus propranolol
Number of subjects: 56
Study 3883741 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus propranolol
Number of subjects: 56
Study 30791884 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone invitation
Number of subjects: 4614
Study 30791884 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised letter
Number of subjects: 4614
Study 30791884 — intervention group
Group type: COMPARATOR
Intervention: Standard letter (control)
Number of subjects: 4614
Study 29426388 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based occupational therapy intervention
Number of subjects: 30
Study 26002786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Dressing (PD)
Number of subjects: 1650
Study 26002786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Device (PCD)
Number of subjects: 1650
Study 26002786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary Compression Pad Device (RCD)
Number of subjects: 1650
Study 23579002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) supplementation (0.3 g/kg body mass)
Number of subjects: 20
Study 23579002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin)
Number of subjects: 20
Study 23579002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) supplementation
Number of subjects: 20
Study 23573950 — intervention group
Group type: EXPERIMENTAL
Intervention: Givinostat 50 mg/d
Number of subjects: 44
Study 23573950 — intervention group
Group type: EXPERIMENTAL
Intervention: Givinostat 100 mg/d
Number of subjects: 44
Study 23573950 — intervention group
Group type: COMPARATOR
Intervention: Hydroxycarbamide (HC)
Number of subjects: 44
Study 19912183 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 20 mg once daily
Number of subjects: 221
Study 19912183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 18825471 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 10 months
Number of subjects: 57
Study 16626265 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual video review
Number of subjects: 128
Study 16626265 — intervention group
Group type: COMPARATOR
Intervention: Group video review
Number of subjects: 128
Study 12745638 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer patients with a fixed view of masculinity
Number of subjects: 0
Study 12745638 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer patients
Number of subjects: 0
Study 12745638 — intervention group
Group type: COMPARATOR
Intervention: Non-patients
Number of subjects: 0
Study 11224624 — intervention group
Group type: COMPARATOR
Intervention: Chronic pancreatitis patients
Number of subjects: 28
Study 11224624 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pancreatitis patients post-resection
Number of subjects: 28
Study 10205316 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg/day)
Number of subjects: 20
Study 10205316 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 7933523 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem (L-627) administered intravenously at daily doses of 17-37.5 mg/kg for 4-7 consecutive days
Number of subjects: 12
Study 7933523 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem (L-627) at a dose of 6 mg/kg
Number of subjects: 12
Study 7933523 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem (L-627) at a dose of 12 mg/kg
Number of subjects: 12
Study 3063133 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg bolus, then 0.2 mg/kg/min infusion for 10 min)
Number of subjects: 30
Study 3063133 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.3 mg/kg bolus)
Number of subjects: 30
Study 3063133 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg bolus)
Number of subjects: 30
Study 31125155 — intervention group
Group type: EXPERIMENTAL
Intervention: NTP treatment
Number of subjects: 164
Study 31125155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofreliner Primer
Number of subjects: 164
Study 31125155 — intervention group
Group type: EXPERIMENTAL
Intervention: NTP + Sofreliner Primer
Number of subjects: 164
Study 31125155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofreliner Primer + NTP
Number of subjects: 164
Study 28856857 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-remifentanil
Number of subjects: 80
Study 28856857 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-remifentanil
Number of subjects: 80
Study 24556057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Delirium Screening Scale (Nu‐DESC)
Number of subjects: 78
Study 24556057 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonton Assessment Scale (ESAS)
Number of subjects: 78
Study 24556057 — intervention group
Group type: EXPERIMENTAL
Intervention: Memorial Delirium Assessment Scale (MDAS)
Number of subjects: 78
Study 23788632 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (n = 40)
Number of subjects: 80
Study 23788632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study 21764087 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 1272
Study 21764087 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation
Number of subjects: 1272
Study 19436100 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust optimization method for IMRT plans
Number of subjects: 1
Study 19436100 — intervention group
Group type: COMPARATOR
Intervention: Non-robust optimized plan
Number of subjects: 1
Study 16936704 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta‐9‐tetrahydrocannabinol (Delta‐9‐THC)
Number of subjects: 74
Study 16936704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 15238771 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV/r QD
Number of subjects: 649
Study 15238771 — intervention group
Group type: COMPARATOR
Intervention: NFV BID
Number of subjects: 649
Study 11691690 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 12
Study 11691690 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 12
Study 11691690 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 12
Study 9408700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesigyna (50 mg norethisterone enanthate and 5 mg estradiol valerate)
Number of subjects: 357
Study 9408700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate)
Number of subjects: 357
Study 8427367 — intervention group
Group type: EXPERIMENTAL
Intervention: Water running
Number of subjects: 32
Study 8427367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 32
Study 8427367 — intervention group
Group type: COMPARATOR
Intervention: Running training
Number of subjects: 32
Study 31471088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 132
Study 31471088 — intervention group
Group type: COMPARATOR
Intervention: Untreated vitreous floaters
Number of subjects: 132
Study 31471088 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants seeking vitrectomy (previously treated with Nd:YAG)
Number of subjects: 132
Study 31471088 — intervention group
Group type: COMPARATOR
Intervention: Control participants without vitreous floaters
Number of subjects: 132
Study 30073253 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dornase alfa (5 drops each ear twice a day for 7 days)
Number of subjects: 40
Study 30073253 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (5 drops each ear twice a day for 7 days)
Number of subjects: 40
Study 27007392 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g)
Number of subjects: 85
Study 27007392 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ (200 mg)
Number of subjects: 85
Study 27007392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both supplements (n-3 fatty acids and CoQ)
Number of subjects: 85
Study 27007392 — intervention group
Group type: COMPARATOR
Intervention: Control (4 g olive oil)
Number of subjects: 85
Study 27007392 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention plasma F₂-isoprostanes
Number of subjects: 85
Study 24802626 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet group (ICD therapy suspended with a magnet)
Number of subjects: 80
Study 24802626 — intervention group
Group type: COMPARATOR
Intervention: Off group (ICD therapy programmed off)
Number of subjects: 80
Study 22374377 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Ketamine (0.5 mg/kg i.m. bolus followed by 2 μg/kg/min i.v. continuous infusion for 12 h)
Number of subjects: 56
Study 22374377 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 56
Study 20919483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-care self-management support model (ATAS)
Number of subjects: 0
Study 20919483 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group, CG)
Number of subjects: 0
Study 18565884 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 206
Study 18565884 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with 6 months of combined androgen suppression therapy (AST)
Number of subjects: 206